PATENT CLAIM ANALYSIS

Application Number: 15924377
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["530", "300000"]

Abstract:
The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.

Claim (Index 1):
A composition comprising, a peptide or peptidomimetic that binds to the ETS domain of an oncogenic ETS family member gene, a nuclear localization signal (NLS), a cell-penetrating peptide (CPP) domain, and a prostate-selective targeting moiety (PSTM).

Metadata:
- Claim Count in Document: 44.0
- Percentile: 90.0
- Lexical Diversity: 1.36667
- Patent Class: 530.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13024491', '12272865', '13483142', '12716653', '15149780']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6294686234694098
- 35 USC 102 Novelty (BERT): 0.5319887373179777
- Combined Prediction Score: 0.6197206348542666
- Mean Citation Score: 314.34668800000014
- Max Citation Score: 362.29745
- Similarity Product: 218.1927682222784

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test